Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Physician & Payer Forum | US | 2015
How Will U.S. Payer and Prescriber Attitudes Shape This Competitive Market?
The treatment of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in the United States is centered on the use of Roche/Genentech’s Rituxan. This monoclonal antibody (MAb) has demonstrated clear improvements in clinical practice, and is still enjoying significant commercial success nearly two decades after its launch. Recent approvals of small-molecule inhibitors Imbruvica and Zydelig are becoming increasingly entrenched in the NHL and CLL/SLL treatment algorithms, while MAbs developed to challenge Rituxan—Novartis’s Arzerra and Roche/Genentech’s Gazyva—face considerable competition from Rituxan’s dominance in the marketplace.
